Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

Autor: Maroto, P, del Muro, XG, Valverde, C, Pinto, A, Sanchez, A, Guma, J, Alonso, T, del Prado, PM, Vazquez, S, Mellado, B, Aparicio, J, Fernandez-Aramburo, A, Girones, R, Terrasa, J, Spanish Germ Cell Canc Grp

Publikováno v: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Background: Incidence of a second testicular tumor is higher in patients diagnosed with testicular cancer than in the general population. As incidence of unilateral germ cell cancer is increasing worldwide and most of these patients are cured, a grow

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::00595d2a730b916f39e04abd51be8542
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7790

Risk-adapted treatment in clinical stage I testicular seminoma: the third spanish germ cell cancer group study.

Autor: Aparicio J, Maroto P, Del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, Del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR

Publikováno v: Journal of Clinical Oncology; 12/10/2011, Vol. 29 Issue 35, p4677-4681, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis.

Autor: García Adrián S; Medical Oncology Department, Hospital Universtario de Móstoles, C/ Dr. Luis Montes S/N, Madrid 28935, Spain; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain. Electronic address: silvia_g_adrian@hotmail.com., González AR; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., de Castro EM; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Olmos VP; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Morán LO; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Del Prado PM; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario de Basurto, Bilbao, Spain., Fernández MS; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Complejo Universitario de Orense, Orense, Spain., Burón JDC; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital de Torrevieja, Torrevieja, Spain., Escobar IG; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital San Pedro de Alcántara, Cáceres, Spain., Galán JM; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain., Pérez AIF; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain., Neria F; Faculty of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain., Lavin DC; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Hernández BLSV; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario de Basurto, Bilbao, Spain., Jiménez-Fonseca P; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Muñoz Martín AJ; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM), Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Publikováno v: European journal of internal medicine [Eur J Intern Med] 2022 Nov; Vol. 105, pp. 30-37. Date of Electronic Publication: 2022 Aug 02.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Autor: Martín M; Hospital Universitario San Carlos, Madrid, Spain. mmartin@geicam.org, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2006 Aug; Vol. 17 (8), pp. 1205-12. Date of Electronic Publication: 2006 Jun 09.